Skip to main content
Supplement Science
meta analysis1,058 participants

Alpha-Lipoic Acid for Diabetic Neuropathy: Meta-Analysis of 15 RCTs

Reviewed by·PharmD, BCPS

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

TL;DR — Quick Answer

A meta-analysis of 15 RCTs (n=1,058) found that alpha-lipoic acid at 600mg/day significantly reduced Total Symptom Score (TSS) for diabetic neuropathy by 2.45 points compared to placebo (p < 0.001), with meaningful improvements in pain, burning, and numbness within 3-5 weeks.

Key Findings

  • Total Symptom Score (TSS) decreased by 2.45 points vs placebo (95% CI: -3.14 to -1.76, p < 0.001)
  • Pain subscores improved significantly with both oral (600mg/day) and IV (600mg/day) administration
  • The 600mg/day oral dose showed the best risk-benefit ratio; higher doses (1200-1800mg) had more GI side effects without added efficacy
  • Significant symptom improvement was detected as early as 3 weeks with IV and 5 weeks with oral supplementation
  • Nerve conduction velocity showed modest but significant improvement after 6+ months of oral ALA

Study Details

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA — Diabetic Medicine (2004)
IV alpha-lipoic acid 600mg/day for 3 weeks significantly improved neuropathy Total Symptom Score across 4 pooled ALADIN trials
1,258 participantsHigh
Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R — Diabetes Care (2006)
Oral ALA 600mg/day for 5 weeks significantly improved TSS; 1200mg and 1800mg doses were not superior to 600mg
181 participantsHigh

Practical Takeaway

For diabetic neuropathy symptoms, take 600mg of R-alpha-lipoic acid (or 1200mg of racemic ALA) daily on an empty stomach, 30 minutes before a meal. Symptom improvements typically begin within 3-5 weeks. Consistent use for 3-6 months provides the greatest benefit for nerve function recovery.

Summary

A meta-analysis of 15 randomized controlled trials examining the efficacy of alpha-lipoic acid (ALA) for reducing symptoms of diabetic peripheral neuropathy including pain, burning, numbness, and paresthesias.

Related Supplements

Alpha-Lipoic Acid

Frequently Asked Questions

Does alpha-lipoic acid help with diabetic nerve pain?

Yes. A meta-analysis of 15 RCTs found ALA at 600mg/day significantly reduced neuropathy symptoms including pain, burning, and numbness. The Total Symptom Score improved by 2.45 points vs placebo, which is considered clinically meaningful. Both IV and oral forms are effective.

What is the best dose of alpha-lipoic acid for neuropathy?

The SYDNEY 2 trial established 600mg/day as the optimal oral dose. Higher doses (1200mg and 1800mg) did not provide additional symptom relief but increased GI side effects like nausea. Take on an empty stomach for best absorption.

How long does alpha-lipoic acid take to help neuropathy?

IV administration can improve symptoms within 3 weeks. Oral supplementation at 600mg/day typically shows significant improvement within 5 weeks. Nerve conduction velocity improvements require longer treatment (6+ months), suggesting both symptomatic and structural benefits.

Should I take R-lipoic acid or racemic alpha-lipoic acid?

Most clinical trials used racemic (R+S) alpha-lipoic acid at 600mg/day. The R-form is the biologically active enantiomer with approximately twice the bioavailability, so 300mg of R-ALA may be equivalent to 600mg of racemic ALA. Both forms are effective.

Can alpha-lipoic acid prevent diabetic neuropathy from getting worse?

The 4-year NATHAN 1 trial found that oral ALA 600mg/day prevented progression of neuropathy impairments, though it did not significantly improve nerve conduction composite scores. It appears most effective at stabilizing and mildly improving existing neuropathy rather than complete reversal.

References

  1. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. DOI PubMed
  2. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. DOI PubMed
  3. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ (2011). Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. DOI PubMed